Modifications of C-2 on the pyrroloquinoline template aimed at the development of potent herpesvirus antivirals with improved aqueous solubility.
| Autor: | Nieman JA; Global Research and Development, Pfizer, Inc., Kalamazoo, MI 49007, USA. jnieman@naeja.com, Nair SK, Heasley SE, Schultz BL, Zerth HM, Nugent RA, Chen K, Stephanski KJ, Hopkins TA, Knechtel ML, Oien NL, Wieber JL, Wathen MW |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2010 May 15; Vol. 20 (10), pp. 3039-42. Date of Electronic Publication: 2010 Apr 03. |
| DOI: | 10.1016/j.bmcl.2010.03.115 |
| Abstrakt: | A series of C-2 pyrroloquinoline analogs designed to improve aqueous solubility were examined for herpesvirus polymerase and antiviral activity. Several analogs were identified that maintained the antiviral activity of the previous development candidate against HCMV, HSV-1 and VZV, but with significantly improved aqueous solubility. (Copyright 2010 Elsevier Ltd. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect